Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 100 clinical trials
Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

This was an open-label, multi-center, randomized phase 2 study. This is a two-stage design.In the first stage, two dose groups were set up, the 100 mg bid dose group and the 200 mg qd dose group, which were randomized at 1:1, with 50 subjects in each group, and a total …

direct bilirubin
neutrophil count
stem cell transplantation
conjugated bilirubin
polycythemia
  • 5 views
  • 09 Dec, 2021
  • 1 location
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants with Intermediate-2 or High-risk myelofibrosis

  • 0 views
  • 10 Jun, 2021
  • 1 location
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

This is a open label mutli-center open-label study to provide continued supply of itacitinib to participants from Incyte-sponsored studies of itacitinib INCB39110-209 and INCB39110-230. Eligible participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. This …

  • 0 views
  • 22 Oct, 2021
  • 3 locations
Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refratory of Ruxolitinib Treatment.

This was a phase 2, single-arm, open-label, non-randomised, multicentre, study to evaluate the efficacy and safety of Jaktinib in patients with myelofibrosis who were relapsed or refractory of

Accepts healthy volunteers
  • 0 views
  • 10 Dec, 2021
  • 1 location
A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis

This is a global, Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of selinexor plus ruxolitinib in treatment naïve myelofibrosis (MF) participants. The study will be

  • 0 views
  • 12 May, 2022
  • 5 locations
  • 0 views
  • 23 May, 2022
  • 16 locations
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet <50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor

  • 0 views
  • 25 May, 2022
  • 1 location
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the

  • 0 views
  • 28 May, 2022
  • 1 location
Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in patients with an MPN who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102 and IMG-7289-CTP-201 (referred to hereafter as 'feeder studies').

  • 0 views
  • 24 Mar, 2022
  • 1 location
Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated

colony stimulating factor
neutrophil count
direct bilirubin
essential thrombocythemia
anemia
  • 22 views
  • 24 Jun, 2021
  • 1 location